|
1
|
Lee JA, Lim J, Jin HY, Park M, Park HJ,
Park JW, Kim JH, Kang HG and Won YJ: Osteosarcoma in adolescents
and young adults. Cells. 10(2684)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Balach T, Stacy GS and Peabody TD: The
clinical evaluation of bone tumors. Radiol Clin North Am.
49:1079–1093. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Carrle D and Bielack SS: Current
strategies of chemotherapy in osteosarcoma. Int Orthop. 30:445–451.
2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zoumpoulidou G, Alvarez-Mendoza C, Mancusi
C, Ahmed RM, Denman M, Steele CD, Tarabichi M, Roy E, Davies LR,
Manji J, et al: Therapeutic vulnerability to PARP1,2 inhibition in
RB1-mutant osteosarcoma. Nat Commun. 12(7064)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Astolfi A, Nannini M, Indio V, Schipani A,
Rizzo A, Perrone AM, De Iaco P, Pirini MG, De Leo A, Urbini M, et
al: Genomic database analysis of uterine leiomyosarcoma mutational
profile. Cancers (Basel). 12(2126)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rizzo A, Pantaleo MA, Saponara M and
Nannini M: Current status of the adjuvant therapy in uterine
sarcoma: A literature review. World J Clin Cases. 7:1753–1763.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Rizzo A, Nannini M, Astolfi A, Indio V, De
Iaco P, Perrone AM, De Leo A, Incorvaia L, Di Scioscio V and
Pantaleo MA: Impact of chemotherapy in the adjuvant setting of
early stage uterine leiomyosarcoma: A systematic review and updated
meta-analysis. Cancers (Basel). 12(1899)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Boye K, Longhi A, Guren T, Lorenz S, Næss
S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, et al:
Pembrolizumab in advanced osteosarcoma: Results of a single-arm,
open-label, phase 2 trial. Cancer Immunol Immunother. 70:2617–2624.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Davis KL, Fox E, Merchant MS, Reid JM,
Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ and Mackall
CL: Nivolumab in children and young adults with relapsed or
refractory solid tumours or lymphoma (ADVL1412): A multicentre,
open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21:541–550.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Monga V, Dodd R, Scherer A, Gutierrez WR,
Tanas M, Mott SL and Milhem M: Phase Ib study of decitabine in
combination with gemcitabine in treatment of advanced soft tissue
and bone sarcomas. J Clin Oncol. 38:11550. 2020.
|
|
13
|
Krishnadas DK, Shusterman S, Bai F, Diller
L, Sullivan JE, Cheerva AC, George RE and Lucas KG: A phase I trial
combining decitabine/dendritic cell vaccine targeting MAGE-A1,
MAGE-A3 and NY-ESO-1 for children with relapsed or
therapy-refractory neuroblastoma and sarcoma. Cancer Immunol
Immunother. 64:1251–1260. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chi SN, Yi JS, Williams PM, Roy-Chowdhuri
S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, et
al: Tazemetostat in patients with tumors with alterations in EZH2
or the SWI/SNF complex: Results from NCI-COG pediatric MATCH trial
Arm C (APEC1621C). J Clin Oncol. 40 (16 Suppl)(10009)2022.
|
|
15
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schwartzberg L, Kim ES, Liu D and Schrag
D: Precision oncology: Who, how, what, when, and when not? Am Soc
Clin Oncol Educ Book. 37:160–169. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gagan J and Van Allen EM: Next-generation
sequencing to guide cancer therapy. Genome Med.
7(80)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chen X, Bahrami A, Pappo A, Easton J,
Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al:
Recurrent somatic structural variations contribute to tumorigenesis
in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Czarnecka AM, Synoradzki K, Firlej W,
Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P:
Molecular biology of osteosarcoma. Cancers (Basel).
12(2130)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Leite C, Delmonico L, Alves G, Gomes RJ,
Martino MR, Silva AR, Moreira ADS, Maioli MC, Scherrer LR, Bastos
EF, et al: Screening of mutations in the additional sex combs like
1, transcriptional regulator, tumor protein p53, and KRAS
proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of
patients with myelodysplastic syndrome. Biomed Rep. 7:343–348.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pestana RC, Groisberg R, Roszik J and
Subbiah V: Precision oncology in sarcomas: Divide and conquer. JCO
Precis Oncol. 3(PO.18.00247)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bousoik E and Aliabadi HM: ‘Do We Know
Jack’ about JAK? A closer look at JAK/STAT signaling pathway. Front
Oncol. 8(287)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hu X, Li J, Fu M, Zhao X and Wang W: The
JAK/STAT signaling pathway: From bench to clinic. Signal Transduct
Target Ther. 6(402)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Albacker LA, Wu J, Smith P, Warmuth M,
Stephens PJ, Zhu P, Yu L and Chmielecki J: Loss of function JAK1
mutations occur at high frequency in cancers with microsatellite
instability and are suggestive of immune evasion. PLoS One.
12(e0176181)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Carvalho TG, Carvalho AC, Maia DCC, Ogawa
JK, Carvalho AL and Vettore AL: Search for mutations in signaling
pathways in head and neck squamous cell carcinoma. Oncol Rep.
30:334–340. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Corte CMD, Viscardi G, Liello R, Fasano M,
Martinelli E, Troiani T, Ciardiello F and Morgillo F: Role and
targeting of anaplastic lymphoma kinase in cancer. Mol Cancer.
17(30)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ordulu Z, Giunta P, Hung WT, Hung YP,
Simon J, Fintelmann FJ, Lennerz JK, Naxerova K and Cote GM:
Sensitivity to ALK-directed therapy in osteosarcoma with an
acquired ALK rearrangement. JCO Precis Oncol.
7(e2300287)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Takeyasu Y, Okuma HS, Kojima Y, Nishikawa
T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, et
al: Impact of ALK inhibitors in patients with ALK-rearranged
nonlung solid tumors. JCO Precis Oncol.
5(PO.20.00383)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pan ZW, Wang XJ, Chen T, Ding XW, Jiang X,
Gao Y, Mo WJ, Huang Y, Lou CJ and Cao WM: Deleterious mutations in
DNA repair gene FANCC exist in BRCA1/2-negative Chinese familial
breast and/or ovarian cancer patients. Front Oncol.
9(169)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Noguchi K, Ikawa Y, Takenaka M, Sakai Y,
Fujiki T, Kuroda R, Ikeda H, Abe T, Sakai S and Wada T: Acquired
L1196M ALK mutation in anaplastic lymphoma kinase-positive
anaplastic large cell lymphoma during alectinib administration.
EJHaem. 4:305–308. 2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Machlowska J, Kapusta P, Baj J, Morsink
FHM, Wołkow P, Maciejewski R, Offerhaus GJA and Sitarz R:
High-throughput sequencing of gastric cancer patients: Unravelling
genetic predispositions towards an early-onset subtype. Cancers
(Basel). 12(1981)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Taher MM, Hassan AA, Saeed M, Jastania RA,
Nageeti TH, Alkhalidi H, Dairi G, Abduljaleel Z, Athar M,
Bouazzaoui A, et al: Next generation DNA sequencing of atypical
choroid plexus papilloma of brain: Identification of novel
mutations in a female patient by Ion Proton. Oncol Lett.
18:5063–5076. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Choi YL, Soda M, Yamashita Y, Ueno T,
Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H,
et al: EML4-ALK mutations in lung cancer that confer resistance to
ALK inhibitors. N Engl J Med. 363:1734–1739. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Doebele RC, Pilling AB, Aisner DL,
Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ,
Heasley LE, Franklin WA, et al: Mechanisms of resistance to
crizotinib in patients with ALK gene rearranged non-small cell lung
cancer. Clin Cancer Res. 18:1472–1482. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wegert J, Ishaque N, Vardapour R, Geörg C,
Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, et al:
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA
microprocessor complex underlie high-risk blastemal type Wilms
tumors. Cancer Cell. 27:298–311. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Dai S, Zhou Z, Chen Z, Xu G and Chen Y:
Fibroblast growth factor receptors (FGFRs): Structures and small
molecule inhibitors. Cells. 8(614)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Su N, Jin M and Chen L: Role of FGF/FGFR
signaling in skeletal development and homeostasis: Learning from
mouse models. Bone Res. 2(14003)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Barøy T, Chilamakuri CSR, Lorenz S, Sun J,
Bruland ØS, Myklebost O and Meza-Zepeda LA: Genome analysis of
osteosarcoma progression samples identifies FGFR1 overexpression as
a potential treatment target and CHM as a candidate tumor
suppressor gene. PLoS One. 11(e0163859)2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Brown LM, Ekert PG and Fleuren EDG:
Biological and clinical implications of FGFR aberrations in
paediatric and young adult cancers. Oncogene. 42:1875–1888.
2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Davis LE, Bolejack V, Ryan CW, Ganjoo KN,
Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, et
al: Randomized double-blind phase II study of Regorafenib in
patients with metastatic osteosarcoma. J Clin Oncol. 37:1424–1431.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Duffaud F, Mir O, Boudou-Rouquette P,
Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E,
Italiano A, Collard O, et al: Efficacy and safety of regorafenib in
adult patients with metastatic osteosarcoma: A non-comparative,
randomised, double-blind, placebo-controlled, phase 2 study. Lancet
Oncol. 20:120–133. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Du X, Xie Y, Xian CJ and Chen L: Role of
FGFs/FGFRs in skeletal development and bone regeneration. J Cell
Physiol. 227:3731–3743. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Xue Y, Sun A, Mekikian PB, Martin J,
Rimoin DL, Lachman RS and Wilcox WR: FGFR3 mutation frequency in
324 cases from the international skeletal dysplasia registry. Mol
Genet Genomic Med. 2:497–503. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wen X, Li X, Tang Y, Tang J, Zhou S, Xie
Y, Guo J, Yang J, Du X, Su N and Chen L: Chondrocyte FGFR3
regulates bone mass by inhibiting osteogenesis. J Biol Chem.
291:24912–24921. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Mansour H, Ouhajjou A, Bajic VB and
Incitti R: Next-Generation sequencing at high sequencing depth as a
tool to study the evolution of metastasis driven by genetic change
events of lung squamous cell carcinoma. Front Oncol.
10(1215)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kassem NM, Kassem HA, Selim H and Hafez M:
Targeted next generation sequencing provides insight for the
genetic alterations in liquid biopsy of Egyptian brain tumor
patients. Egypt J Med Hum Genet. 23(23)2022.
|
|
47
|
Loriguet L, Morisse MC, Dremaux J, Collet
L, Attencourt C, Coutte A, Boone M, Sevestre H, Galmiche A, Gubler
B, et al: Combining genomic analyses with tumour-derived slice
cultures for the characterization of an EGFR-activating kinase
mutation in a case of glioblastoma. BMC Cancer.
18(964)2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Moazeni-Roodi A, Sarabandi S, Karami S,
Hashemi M and Ghavami S: An updated meta-analysis of the
association between fibroblast growth factor receptor 4
polymorphisms and susceptibility to cancer. Biosci Rep.
40(BSR20192051)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sun Y, Yue L, Xu P and Hu W: An overview
of agents and treatments for PDGFRA-mutated gastrointestinal
stromal tumors. Front Oncol. 12(927587)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Velghe AI, Cauwenberghe SV, Polyansky AA,
Chand D, Montano-Almendras CP, Charni S, Hallberg B, Essaghir A and
Demoulin JB: PDGFRA alterations in cancer: Characterization of a
gain-of-function V536E transmembrane mutant as well as
loss-of-function and passenger mutations. Oncogene. 33:2568–2576.
2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wagner AJ, Kindler H, Gelderblom H,
Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA,
Peeters M, Reichardt P, et al: A phase II study of a human
anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously
treated patients with metastatic gastrointestinal stromal tumors.
Ann Oncol. 28:541–546. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Armstrong AE, Walterhouse DO, Leavey PJ,
Reichek J and Walz AL: Prolonged response to sorafenib in a patient
with refractory metastatic osteosarcoma and a somatic PDGFRA D846V
mutation. Pediatr Blood Cancer. 66(e27493)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Guimarães GM, Tesser-Gamba F, Petrilli AS,
Donato-Macedo CRP, Alves MTS, de Lima FT, Garcia-Filho RJ, Oliveira
R and Toledo SRC: Molecular profiling of osteosarcoma in children
and adolescents from different age groups using a next-generation
sequencing panel. Cancer Genet. 258-259:85–92. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Jin R, Peng L, Shou J, Wang J, Jin Y,
Liang F, Zhao J, Wu M, Li Q, Zhang B, et al: EGFR-Mutated squamous
cell lung cancer and its association with outcomes. Front Oncol.
11(680804)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Liu H, Zhang B and Sun Z: Spectrum of EGFR
aberrations and potential clinical implications: Insights from
integrative pan-cancer analysis. Cancer Commun (Lond). 40:43–59.
2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Nan X, Xie C, Yu X and Liu J: EGFR TKI as
first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Oncotarget.
8:75712–75726. 2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Geißler AL, Geißler M, Kottmann D, Lutz L,
Fichter CD, Fritsch R, Weddeling B, Makowiec F, Werner M and
Lassmann S: ATM mutations and E-cadherin expression define
sensitivity to EGFR-targeted therapy in colorectal cancer.
Oncotarget. 8:17164–17190. 2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Capalbo C, Belardinilli F, Filetti M,
Parisi C, Petroni M, Colicchia V, Tessitore A, Santoni M, Coppa A,
Giannini G and Marchetti P: Effective treatment of a
platinum-resistant cutaneous squamous cell carcinoma case by EGFR
pathway inhibition. Mol Clin Oncol. 9:30–34. 2018.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Verrienti A, Grani G, Sponziello M, Pecce
V, Damante G, Durante C, Russo D and Filetti S: Precision oncology
for RET-related tumors. Front Oncol. 12(992636)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kovac M, Woolley C, Ribi S, Blattmann C,
Roth E, Morini M, Kovacova M, Ameline B, Kulozik A, Bielack S, et
al: Germline RET variants underlie a subset of paediatric
osteosarcoma. J Med Genet. 58:20–24. 2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Sklarz LM, Wittke C, Krohn S, GROßE-Thie
C, Junghanss C, Escobar HM and Glaeser H: Genetic mutations in a
patient with chronic myeloid leukemia showing blast crisis 10 years
after presentation. Anticancer Res. 38:3961–3966. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Huang L, Guo Z, Wang F and Fu L: KRAS
mutation: From undruggable to druggable in cancer. Signal Transduct
Target Ther. 6(386)2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Chen C, Shi Q, Xu J, Ren T, Huang Y and
Guo W: Current progress and open challenges for applying tyrosine
kinase inhibitors in osteosarcoma. Cell Death Discov.
8(488)2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Tian Z, Niu X and Yao W: Receptor tyrosine
kinases in osteosarcoma treatment: Which is the key target? Front
Oncol. 10(1642)2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Borrero LJH and El-Deiry WS: Tumor
suppressor p53: Biology, signaling pathways, and therapeutic
targeting. Biochim Biophys Acta Rev Cancer.
1876(188556)2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Mirabello L, Yeager M, Mai PL,
Gastier-Foster JM, Gorlick R, Khanna C, Patiño-Garcia A,
Sierrasesúmaga L, Lecanda F, Andrulis IL, et al: Germline TP53
variants and susceptibility to osteosarcoma. J Natl Cancer Inst.
107(djv101)2015.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Hameed M and Mandelker D: Tumor syndromes
predisposing to osteosarcoma. Adv Anat Pathol. 25:217–222.
2018.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Wunder JS, Gokgoz N, Parkes R, Bull SB,
Eskandarian S, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey
JH, et al: TP53 mutations and outcome in osteosarcoma: a
prospective, multicenter study. J Clin Oncol. 23:1483–1490.
2005.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Ribi S, Baumhoer D, Lee K, Edison Teo AS,
Madan B, Zhang K, Kohlmann WK, Yao F, Lee WH, et al: TP53 intron 1
hotspot rearrangements are specific to sporadic osteosarcoma and
can cause Li-Fraumeni syndrome. Oncotarget. 6:7727–7740.
2015.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Bousquet M, Noirot C, Accadbled F, de
Gauzy JS, Castex MP, Brousset P and Gomez-Brouchet A: Whole-exome
sequencing in osteosarcoma reveals important heterogeneity of
genetic alterations. Ann Oncol. 27:738–744. 2016.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Balmaña J, Nomdedéu J, Díez O, Sabaté JM,
Balil A, Pericay C, López JJ, Brunet J, Baiget M and Alonso C:
Description of a new TP53 gene germline mutation in a family with
the Li-Fraumeni syndrome. Genetic counselling to healthy mutation
carriers. Med Clin (Barc). 119:497–499. 2002.PubMed/NCBI View Article : Google Scholar : (In Spanish).
|
|
73
|
Haslam A, Kim MS and Prasad V: Updated
estimates of eligibility for and response to genome-targeted
oncology drugs among US cancer patients, 2006-2020. Ann Oncol.
32:926–932. 2021.PubMed/NCBI View Article : Google Scholar
|
